Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Xilio Therapeutics (NASDAQ:XLO)

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Xilio Therapeutics (NASDAQ:XLO)

WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.…

Xilio Therapeutics Announces Inducement Grant UnderNasdaq Listing Rule 5635(c)(4)

May 02, 2025 16:30 ET  | Source: Xilio Therapeutics, Inc. WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 […]

Xilio Therapeutics Awards 5,000 Share Stock Option Grant at $0.755 Per Share to New Employee

New employee receives stock options worth 5,000 shares at $0.755 per share. Explore vesting schedule and compliance details under Nasdaq Rule 5635(c)(4). See terms.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Arcutis Biotherapeutics

WESTLAKE VILLAGE, Calif., May 02, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 26,500 restricted stock units of Arcutis’ common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted u…